Syndax Pharmaceuticals (SNDX) Gains from Sales and Divestitures (2021 - 2025)
Syndax Pharmaceuticals (SNDX) recorded quarterly Gains from Sales and Divestitures of $410707.0 in Q4 2025, up 380.39% quarter-over-quarter from $85495.0 in Q4 2024, and up 380.39% on a YoY basis from $85495.0 in Q4 2024.
Syndax Pharmaceuticals (SNDX) Gains from Sales and Divestitures (2021 - 2025) Analysis & Trends
Syndax Pharmaceuticals' Gains from Sales and Divestitures history runs 5 years deep, the most recent figure standing at $410707.0 for Q4 2025.
- In Q4 2025, Gains from Sales and Divestitures rose 380.39% year-over-year to $410707.0; the TTM figure through Dec 2025 stood at $410707.0 (up 380.39% YoY), while the FY2025 annual figure was $410707.0, up 380.39% from the prior year.
- Gains from Sales and Divestitures was $410707.0 for Q4 2025 at Syndax Pharmaceuticals, up from $85495.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $410707.0 in Q4 2025 to a low of $3750.0 in Q1 2022.
- Historically, Gains from Sales and Divestitures has averaged $55932.5 across 5 years, with a median of $9102.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Gains from Sales and Divestitures plunged 76.51% in 2023, then soared 839.3% in 2024.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $5500.0 in 2021, then jumped by 604.55% to $38750.0 in 2022, then slumped by 76.51% to $9102.0 in 2023, then jumped by 839.3% to $85495.0 in 2024, then surged by 380.39% to $410707.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $410707.0 (Q4 2025), $85495.0 (Q4 2024), and $9102.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Syndax Pharmaceuticals | 1.69 Bn | 1.34 Bn | 53.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 410,707.00 |
| Dec 31, 2025 | 410,707.00 |
| Dec 31, 2024 | 85,495.00 |
| Dec 31, 2024 | 85,495.00 |
| Dec 31, 2023 | 9,102.00 |
| Dec 31, 2023 | 9,102.00 |
| Sep 30, 2023 | 9,102.00 |
| Sep 30, 2023 | 9,102.00 |
| Jun 30, 2023 | 6,602.00 |
| Jun 30, 2023 | 6,602.00 |
| Mar 31, 2023 | 5,000.00 |
| Mar 31, 2023 | 5,000.00 |
| Dec 31, 2022 | 38,750.00 |
| Dec 31, 2022 | 38,750.00 |
| Sep 30, 2022 | 37,500.00 |
| Sep 30, 2022 | 37,500.00 |
| Jun 30, 2022 | 3,750.00 |
| Jun 30, 2022 | 3,750.00 |
| Mar 31, 2022 | 3,750.00 |
| Mar 31, 2022 | 3,750.00 |